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Abstract 
Nanomaterial technologies are becoming increasingly prevalent in consumer and industrial applications, 
including drug delivery, energy harvesting, environmental applications, and medicine due to their unique 
physiochemical properties. As nanomaterial use increases, so too does human exposure. This has made it 
progressively more important to understand the toxicological effects of nanomaterials and their interactions 
with the human body. Silver nanoparticles (AgNPs) are one of the most commonly used nanomaterials due 
to their antibacterial properties. As inhalation is one of the most common exposure routes, understanding 
the toxicity of these AgNPs on lung tissue was studied. Using A549 cells for a lung tissue model, AgNPs of 
two sizes, 10 nm and 50 nm, and two different coatings, citrate and polyvinylpyrrolidone (PVP), were 
studied. Toxicity analysis was performed to determine the effects of dose on cell viability. Pharmacokinetic 
profiles in static conditions were developed using deposition analysis. Future work will include deposition 
analysis on dynamic conditions to replicate conditions within a body. This work is part of a larger project to 
develop an enhanced microcellular model (EMM) to bridge the in vitro - in vivo gap and characterize 
nanomaterials, evaluate biological responses, and develop pharmacokinetic profiles.  
 
 
Acknowledgements 
I would like to thank Dr. Comfort for guiding me through this entire process and sharing her knowledge 
through research. From the start, she pushed me beyond my comfort zone, encouraging my development of 
research skills and independence.  
 
I would like to thank the University of Dayton Chemical Engineering Department for providing me with 
the knowledge, skills, and opportunity to embrace this project. I would also like to thank the University of 
Dayton Summer Undergraduate Research Experience for the funding and opportunity to continue my thesis 
research outside of school semesters.  
 
I would like to thank my family and friends for their support through this project. I am grateful for the 
encouragement they provided, through motivation to push through frustrating points and expand my love of 
and drive for research.  
 
 
 
Page | i 
 
Table of Contents 
 
ABSTRACT .......................................................................................................... Title Page 
DEDICATION ...................................................................................................... Title Page 
ACKNOWLEDGEMENTS .................................................................................. Title Page 
LIST OF FIGURES ............................................................................................................ ii 
LIST OF ABBREVIATIONS ............................................................................................. ii 
Background ........................................................................................................................1 
 Nanoparticle Properties...........................................................................................1 
 Applications of Nanoparticles..................................................................................1 
 Silver Nanoparticle Toxicity ....................................................................................2 
 Nanoparticle Coatings .............................................................................................3 
 Cell Viability Analysis..............................................................................................3 
 Silver Nanoparticle Deposition................................................................................4 
 Conclusions ..............................................................................................................4 
 References ................................................................................................................5 
Experimental Procedures ..................................................................................................7 
 Introduction..............................................................................................................7 
 Cell Culture ..............................................................................................................7 
 Cell Counting and Plating .......................................................................................7 
 Toxicity Testing – MTS Assay ..................................................................................8 
 Deposition Analysis .................................................................................................9 
Results and Discussion .....................................................................................................10 
 Introduction............................................................................................................10 
 Cytotoxicity ............................................................................................................10 
 Pharmacokinetic Profiles.......................................................................................11 
 Discussion ..............................................................................................................13 
 Conclusions ............................................................................................................14 
 References ..............................................................................................................14 
 
 
Page | ii 
 
List of Figures 
 
Figure 1: Primary factors of nanoparticle toxicity ..............................................................2 
Figure 2: Diagram of general thesis project concept ........................................................10 
Figure 3: A549 cell viability 24 hours after 10 nm AgNP exposure at varying 
concentrations and coatings ...................................................................................11 
Figure 4: Absorbance calibration curves ..........................................................................12 
Figure 5: Deposition profiles of citrate and PVP coated 10 nm silver nanoparticles  
 in a static environment ...........................................................................................13 
 
List of Abbreviations 
 
A549   Human Alveolar Basal Epithelial Cells 
AgNP   Silver Nanoparticle 
FBS   Fetal Bovine Serum 
MTS   CellTiter 96 Aqueous One Solution Assay 
NP   Nanoparticle 
PBS   Phosphate Buffer Solution 
PVP   Polyvinylpyrrolidone  
TEM   Transmission Electron Microscope 
UV-Vis  Ultraviolet-visible Spectroscopy 
P a g e  | 1 
 
Background 
 
 Nanoparticle Properties: 
Nanomaterials are defined as any material that has a dimension of 100 nm or less 
in size1. In addition to their small size, there are also a wide variety of shapes, 
including nanotubes, nanowire, spheres, ovals, cubes, prisms, helices, and pillars2. 
Nanomaterials typically exhibit very different properties than bulk material 
properties. This can mainly be attributed to the high surface area to volume ratio 
of nanomaterials1. Due to their small size and ability to attach substances to the 
surface, known as functionalization, they have the unique capability of interacting 
with the body1.  
 
The main classes of nanoparticles include carbon based nanoparticles, such as 
fullerenes and carbon nanotubes, metal nanoparticles, ceramic nanoparticles, 
including inorganic nonmetallic solids, semiconductor nanoparticles, polymeric 
nanoparticles, which are usually organic based, and lipid based nanoparticles3.  
 
Applications of Nanoparticles: 
Due to the special properties of nanoparticles, they have innumerable applications 
across many fields. These include medicine, improved drug delivery, cancer 
diagnosis, environmental contaminant absorption, electrical equipment, energy 
harvesting, and coatings, lubricants, and adhesives3. Nanoparticles used in drug 
delivery provide targeted and controlled release of pharmaceuticals based upon 
the coatings and proteins attached to the surface of the particles. Cancer treatment 
and diagnosis uses the enhanced light scattering and absorption of nanoparticles, 
known as plasmonic potential, to convert light to heat in laser photo thermal 
therapy. Environmental containment absorption exploits the high surface areas of 
nanoparticles to absorb contaminants and trap them during aggregation. Energy 
harvesting uses nanoparticles to generate energy from photoelectrochemical and 
electrochemical water splitting, in addition to the conversion of mechanical 
energy to electricity in nanogenerators. Nanoparticles are also incorporated into 
metal and polymer matrix to develop coatings and lubricants for mechanical 
industries.  
 
Nanoparticles such as silver, copper, zinc, and magnesium nanoparticles have 
antimicrobial properties. Silver nanoparticles (AgNPs) are among the most widely 
used and studied nanoparticles4. Exploiting their antimicrobial properties, silver 
nanoparticles are often used in medicines, clothing, industrial, household, 
cleaning items, sensors, and personal care products5,6.  
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Silver Nanoparticle Toxicity: 
In addition to the antimicrobial effects of silver nanoparticles, there are also 
concerns of its toxicity. As AgNPs become more and more popular in industry, 
exposure levels are greatly increased. Under normal conditions, AgNPs oxidize, 
shedding silver ions (Ag+), which has been indicated to be the principle 
mechanism of toxicity in cells7,8. Due to the high surface areas of the smaller 
nanoparticles, there is more silver shedding, and therefore more toxicity7. Because 
of this, understanding how the nanoparticles interact with the body and the 
mechanism of toxicity becomes important. However, specific toxicity depends on 
a wide variety of factors. Identified factors of toxicity, shown in Figure 1, include 
nanoparticle size, aggregation, exposure duration, agglomerate size, media 
composition, environmental pH, crystallinity, surface functionalization, 
concentration, and the organism exposed2,8. Because there are so many factors 
involved, it makes it difficult to predict the toxicity of each nanoparticle, and 
therefore extensive testing is required for each unique NP.   
 
 
Figure 1: Primary factors of nanoparticle toxicity 
 
One primary entry route for AgNPs into the body is through the lungs2,9. Due to 
the alveoli having such a large surface area, it is then easy for the nanoparticles to 
enter the bloodstream and circulate to other parts of the body2. Human alveolar 
basal epithelial cells (A549) are a viable option to assess this toxicity. The lungs 
are often one of the first areas of exposure to AgNPs, and understanding the 
toxicity of them in the lungs can help to guide later bodily interactions and 
exposure. A549 cells are a cancer line model, and can be indicative of the 
biological responses of lung cells after exposure.  
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Nanoparticle Coatings: 
Silver nanoparticles commonly have a coating applied to the outside of the 
particles, utilizing the enhanced surface area to change the properties of the 
nanoparticle. These coatings play a major role in the interactions that the 
nanoparticles have with their environment. Coatings can help to prevent unwanted 
interactions with the environment and with the nanoparticles themselves, which 
helps to stabilize them. This stabilization can be provided from oxidation by the 
coatings, or from steric hindrance or ionic stabilization, depending on the type of 
coating applied10. The types of coatings are cationic, anionic, proteins, or 
polymers. The toxicity of the nanoparticles have been found to be directly linked 
with the type of coating, with studies finding the cationic nanoparticles to be the 
most toxic, followed by the proteins, then anionic, then polymer coatings. This 
could be due to the stronger interactions of the positively charged nanoparticles 
with the negatively charged cell surface10.  
Two of the most commonly used coatings include citrate and 
polyvinylpyrrolidone (PVP). Both citrate and PVP are nontoxic on their own7. 
PVP is a large polymer with available nitrogen and oxygen binding sites. These 
sites provide binding locations for the silver that is released from the 
nanoparticles, therefore reducing the toxicity of the nanoparticle7. By bonding the 
Ag+ and H+ ions, a surface layer is formed that prevents agglomeration through 
steric hinderance7. Citrate coatings, while also helping to stabilize the AgNPs, do 
so through different mechanisms. The citrate coating is much smaller than the 
PVP. It acts as a reducing agent and stabilizes the nanoparticles through 
electrostatic repulsion7.  
 
Cell Viability Analysis: 
In order for the toxicity of the nanoparticles to be identified, the viability of cells 
after exposure needs to be quantified. One way to do so is through an MTS assay. 
The compound 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium is known as MTS. MTS is a type of tetrazolium salt 
that is converted to formazan, which is soluble in aqueous solutions, when 
exposed to NADH and NADPH11,12. When a cell is healthy and functioning 
properly, dehydrogenase enzymes in the mitochondria such as malate 
dehydrogenase and citrate dehydrogenase are used during catabolism for ATP 
generation. This occurs in the mitochondrial membrane and also produces NADH 
and NADPH11. Therefore, the production of formazan is linked directly to the 
production of NADH and NADPH, linking it to living cell counts. The formazan 
salt produced has a deep purple color, which absorbs light in the high 400’s nm 
range. The more formazan produced, the higher the absorbance, and therefore the 
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higher the living cell count. Using a control well with no addition of 
nanoparticles, a base absorbance can be found for normally functioning cells. 
From there, with the addition of varying levels of nanoparticles, the toxicity can 
be determined from the changes in the absorbance of light.  
 
Silver Nanoparticle Deposition: 
Understanding dosimetry is important in understanding and predicting the toxicity 
of nanoparticles. The dosimetry of chemicals is well understood in vitro due to the 
fact that the chemical properties of traditional chemicals do not significantly 
change in solution and don’t have macroscale physical characteristics that need to 
be understood or taken into account, as nanoparticles do13. Also unlike chemicals, 
nanoparticles settle, diffuse, aggregate, and change surface chemistry over time, 
which significantly changes the way they interact with and affect cells. Just using 
the administered dose of nanoparticles ignores the ability of NPs to change 
physical parameters, sediment, and diffuse over time14. Nanoparticles can settle 
differently over time, depending on their size, density, and surface chemistry, 
which means the larger and more dense particles are delivered and interact with 
cells much more quickly than the smaller particles13. Therefore, time is an 
important factor in understanding the deposition and the development of 
pharmacokinetic profiles. Since nanoparticles are suspended within a fluid, or 
media specifically in in vitro analysis, it can take up to hundreds of hours to 
deliver the entirety of the dose to the cells, depending upon the type of 
nanoparticle14. These suspended nanoparticles have little to no interaction with 
the adherent cells and therefore need to be accounted for during dosimetry 
analysis. The fractional deposition and delivered dose can be measured as a 
function of time, used in developing pharmacokinetic profiles14. Accounting for 
the administered dose, the solution dose, and the deposited dose pulls together a 
more cohesive picture of how the nanoparticles are affecting the exposed cells15. 
Comparing pharmacokinetic profiles of nanoparticles of the very similar 
characteristics can help to indicate how different characteristics affect dosimetry 
and toxicity.  
 
Conclusions: 
Due to the wide applicability and flexibility of nanomaterials, they have to 
potential to, and already are, changing the face of many different industries. This 
can no doubt account for the rapid speed at which their popularity and use is 
growing. However, understanding how these foreign objects interact with and 
affect the human body and its’ systems is crucial in order to minimize and prevent 
harmful effects. Additionally, due to the dynamic and macroscale properties of 
AgNPs, it is important to study the deposition of the NPs and develop 
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pharmacokinetic profiles. Further studies will help to develop the knowledge 
around nanomaterials that is required for their extensive use.  
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Experimental Procedures 
 
Introduction:  
This thesis is aimed at determining the toxicity and deposition of silver 
nanoparticles within a static lung cell model, using A549 cells. In order to 
determine this, baseline toxicity testing must be performed. Each NP coating and 
size requires its own calibration and analysis. Pharmacokinetic profiles can then 
be created, using known concentrations and toxicity as a baseline. Exact 
procedures followed during research are outlined in the following section, 
including the general goal of each procedure.  
 
Cell Culture: 
Aseptic mammalian cell culture procedure was used to grow and maintain the 
A549 cells . Cell culture was performed every 3-4 days and only healthy, normal 
cells were used during experimental testing.  
 
Procedure: 
1. The A549 human alveolar basal epithelial cells were purchased from 
American Type Cell Culture (ATCC).  
2. The A549 cells were grown in RPMI 1640 media containing 10% fetal bovine 
serum (FBS) and 2% penicillin/ streptomycin in petri dishes. Cells were 
grown in an incubator kept at 5% CO2 and 37 oC.  
3. Once cells were determined to be 80-90% confluent by light microscope 
visualization, the cells were prepped to be split.  
4. Media was removed from the petri dish and the cells were washed with 5 mL 
of phosphate buffer solution (PBS).  
5. After the wash, 3 mL of 0.25% trypsin was added and the dish was incubated 
for approximately 5 min to detach the cells from the bottom of the dish.  
6. In order to deactivate the trypsin, 3 mL of media was added to the dish after 
incubation. Cells were thoroughly mixed to break up clumps and to ensure 
even dispersion.  
7. A portion of the cell mixture, depending on desired confluency, was 
transferred to a new petri dish and new media was added to bring the dish to 
bring the total volume to 10 mL.  
8. Steps 3-7 were repeated every 3-4 days as necessary for cell maintenance.  
 
Cell Counting and Plating:  
Cell counting and plating techniques were followed before each test. This ensures 
accurate and repeatable procedures and appropriate, optimized cell densities.  
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Procedure 
1. After cells have grown to about 90% confluency, as visualized by TEM, the 
petri dish was removed from the incubator, washed with PBS, and trypsin was 
added.  
2. The dish was incubated for about 5 minutes to detach the cells and 3 mL of 
media was added to neutralize the trypsin.  
3. Cells were thoroughly mixed to break up clumps and evenly distribute the 
cells in the media.  
4. 10 μL of the cell mixture was transferred to a single well of a 96 well plate. 
Additionally, 10 μL of 0.4% trypan blue stain was added to the well and the 
solution was pipetted up and down several times to mix.  
5. 10 μL of the solution was pipetted into a Countess counting slide. The slide 
was inserted into a Countess Cell Counter to determine live cell counts. The 
number of live, dead, and total cells were determined, along with the viability 
percent.  
6. Using the live cell counts, the cell mixture was diluted to the desired 
concentration. The cells were plated into either a 96-well or 6-well plate.  
7. Plates were placed in the incubator for 24 hours to allow the cells to adhere 
and grow to desired confluency.  
 
Toxicity Testing-MTS Assay 
The MTS assay, which is tetrazolium based, indicates the viability of the A549 
cells after they have been exposed to AgNPs. This provides an initial indication of 
cellular response to the nanoparticles.  
 
Procedure 
1. Cells were plated in a 96-well plate as described above at 4x105 cells/well. 
Cells were incubated for 24 hours.  
2. Media was removed from the wells and the cells were washed with PBS.  
3. Silver nanoparticles were diluted from 1000 μg/mL to 1, 5, 15, 50, and 100 
μg/mL to create dosing solutions for toxicity testing.  
4. Each well was dosed with media control or a dosing solution, with 4 wells for 
each dilution. Cells were incubated for 24 hours.  
5. The following day, the MTS assay reagent was thawed at room temperature.  
6. Once thawed, 100 μL of media and 20 μL of MTS reagent per well were 
mixed together. 120 μL of solution was added to each well and the plate was 
incubated for 1-3 hours.  
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7. 60 μL of solution was pipetted off the top of each well and placed into a fresh 
well. The absorbance of each well was read at 490 nm using a 96 well plate 
reader.  
8. Absorbance from 0 μg/mL was assumed to be 100% viability. Cellular 
viability of all other wells was normalized to absorbance from 100% viability.  
 
 
Deposition Analysis 
The percentage of the total administered does of AgNPs that were internalized by 
and/or deposited on the cells, or the deposition of the AgNPs, were determined 
under static conditions.  
 
Procedure: 
1. Cells were plated in a 6-well plate at 1x106 cells/well with a working volume 
of 2.5 mL/well as outlined in Cell Counting and Plating.  
2. Cells were incubated for 24 hours, then washed with PBS.  
3. Dosing solutions of 25 μg/mL were made and wells were dosed at 2.5 
mL/well in 4 wells.  
4. After the set timeframe, 2, 4, 6, 8, 12, 16, 20, and 24 hours, 100 μL of solution 
was pipetted from each well and placed into a well of a 96-well plate. Three 
wells were filled from each well of the 6-well plate.  
5. Spectral absorbance curves of each well was read using UV-Vis, and the peak 
of the curve was taken.  
6. For calibration of absorbance, dosing solutions of 0, 1, 5, 10, 15, 20, 25, and 
50 μg/mL were made and 100 μL of each was pipetted into a 96-well plate.  
  
P a g e  | 10 
 
Results and Discussion 
 
Introduction: 
As nanomaterials develop over time, so does their general use and exposure to 
humans and the environment. Nanoparticles’ wide range of applications cover 
medical, environmental, energy, electrical, and industrial settings. Metallic 
nanoparticles, such as silver, are exploited mainly for their antibacterial 
properties, especially in the medical field1. Some of these applications include 
drug delivery, cancer diagnosis, cleaning products, personal care products, and 
sensors1,2. Many of these applications involve direct exposure to humans and 
therefore could interfere with the healthy behavior of cells and induce possible 
negative effects. Understanding the consequences, effects, and toxicity of this 
exposure becomes vitally more important behind this rise in exposure.  
 
In order to better understand the interactions of silver nanoparticles with the 
human body, this work examined the toxicity and deposition of silver 
nanoparticles in a static lung model at varying concentrations and timeframes. 
 
 
Figure 2: Diagram of general thesis project concept 
 
For several reasons, human carcinoma alveolar basal epithelial cells were selected 
for experimentation. First, the lungs are one of the primary exposure routes for 
AgNPs, which can cause respiratory irritation and long term health effects3. 
Additionally, due to their size, AgNPs can translocate from the lungs, making 
them a gateway to the rest of the body4. Goals of this study include the toxicity of 
various AgNP sizes and coatings, as well as time dependent deposition profiles. 
The following sections outline the findings and results of the study utilizing the 
procedures outlined in the Experimental Procedures section. 
 
Cytotoxicity: 
Since human exposure has increased greatly with the rise of nanoparticles, 
nanotoxicity has become an important aspect of nanotechnology development. In 
order to assess the safety of AgNPs in current and future applications, the cell 
viability of A549 cells were assessed using an MTS assay. Tetrazolium salt is 
Administered 
dose
Solution
doseDeposited
dose
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converted to formazan when exposed to healthy functioning cells5. Due to the 
difference in color between tetrazolium and formazan, the absorbance wavelength 
is read and used to determine the percentage of healthy living cells normalized to 
a 100% living cell reading.  
 
The MTS assay determined cell viability after 24 hours of AgNP exposure at 
varying dose concentrations. As seen in Figure 3, cell viability decreased with 
increasing dosage. At low doses, 1-25μg/mL, cell viability was not compromised. 
At doses above 50 μg/mL for the citrate coating, there was some loss of cell 
viability. With a PVP coating, cell viability was less compromised when 
compared to a dose of the same concentration with a citrate coating, with doses of 
100 μg/mL having a significant impact on cell viability.  
 
 
Figure 3: A549 cell viability 24 hours after 10 nm AgNP exposure at varying 
concentrations and coatings. At 50 μg/mL and higher for citrate and 100 
μg/mL for PVP, cell viability was compromised. Cell viability was slightly 
higher when compared with a citrate coating. * indicates statistical 
significance from control, n=4, p<0.05.  
 
 
Pharmacokinetic Profiles: 
In order to better understand and predict the toxicity of a delivered dose of 
AgNPs, understanding how they interact with an environment is important. 
Because nanoparticles behave very differently than chemicals, with their ability to 
settle, aggregate, diffuse, and change surface chemistry, each nanoparticle must 
be closely studied7. The coating on the nanoparticle also plays a significant role in 
the toxicity and deposition, due to the interactions with the environment. The PVP 
coated nanoparticles are less toxic because of the larger polymer, which binds to 
the silver ions and makes the particles more stable in solution7 . Citrate affects the 
stability and toxicity through steric hinderance and repulsion, settling out faster 
0 2 5 5 0 7 5 1 0 0
0
5 0
1 0 0
C o n c e n tra tio n  (µ g /m l)
C
e
ll
 V
ia
b
il
it
y
 (
%
C
o
n
tr
o
l)
C itra te
P V P
**
*
P a g e  | 12 
 
than the PVP7 . Time plays a major role in the fraction of the delivered dose that 
interacts with the nanoparticle.  
 
After analyzing the toxicity of each delivered dose, a concentration of 25 μg/mL 
was the selected dose to move forward with. This provides a dose that slightly 
affects the viability of the cells, but not to a significant amount. It also is a large 
enough dose to have time effects throughout the entire 24 hours of testing.  
 
The peak of the spectral absorbance curve of media removed from the sample is 
used to indicate how much of the administered dose has interacted with or been 
internalized by the static cells on the bottom of the plate. Known concentration 
sample absorbance readings were taken to create calibration curves, used to 
determine administered doses, seen in Figure 4. Each individual graph was unique 
for each combination of media and silver nanoparticle size/coating sample. 
Graphs were made by taking the absorbance of each known concentration 
between 0 and 50 μg/mL.  
 
 
 
 
Figure 4: Absorbance calibration curves for each media and nanoparticle 
combination from 0 to 50 μg/mL. Figure a) represents citrate and b) 
represents PVP.  
 
Peak absorbance is linearly proportional to the concentration of nanoparticles in 
solution, when absorbance is read at 490 nm with UV-Vis. Curve fitting the data, 
the resulting linear equations can be used to find unknown concentrations of 
AgNPs in solution.  
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Size, shape, and surface chemistry play a vital role in how the nanoparticle 
interacts with the cells. Size affects the settling time of the nanoparticles, as can 
the surface chemistry. Therefore, understanding how the AgNPs settle and 
interact over time is an important aspect of understanding their potential harm to 
cells. The effects of surface chemistry on settling time and interaction can be seen 
in Figure 5.  
 
 
 
 
Figure 5: Deposition profiles of citrate and PVP coated 10 nm silver 
nanoparticles in a static environment. Figure a) represents citrate and b) 
represents PVP.  
 
At an administered dose of 25 μg/mL of 10 nm AgNPs, citrate coated 
nanoparticles almost entirely settle out by 24 hours of exposure. PVP coated 
nanoparticles settle much slower, exhibiting more stable properties in cell culture 
media. Since not all of the administered nanoparticle dose has interactions with 
the cells, understanding the percentage of the administered dose that interacts with 
the cells better quantifies the toxicity levels of the nanoparticle.  
 
Discussion: 
The toxicity and deposition of 10 nm citrate and PVP coated AgNPs in a static 
environment was successfully assessed in this project. The results from the MTS 
assay indicated that at high doses of AgNPs, 50-100 μg/mL, there was a 
significant decrease in cell viability, indicating levels of toxicity. At low levels of 
AgNP exposure, cells exhibited low levels of decreased viability. At 25 μg/mL, 
citrate coated nanoparticles settle out much faster than PVP coated AgNPs.  These 
results suggest that cells exposed to citrate coated nanoparticles are exposed to 
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higher doses of nanoparticles in a static environment. High doses of silver 
nanoparticle exposure will lead to unwanted toxic responses of the cells, and 
ultimately, cell death.  
 
Conclusion: 
The purpose of this research was to identify toxic doses of AgNPs in a static 
environment and develop the corresponding pharmacokinetic profiles. Cancer 
lung tissue was exposed to varying doses of citrate and PVP coated nanoparticles. 
The cellular response was recorded in terms of cell viability to identify toxicity 
levels of each dose. At low concentrations, cellular viability was insignificantly 
altered, only slightly lowering the fraction of live cells. At higher concentrations, 
cell viability was significantly altered, with upwards of 25% of cells no longer 
viable after 24 hours of exposure. Time dependent deposition profiles were 
created for 25 μg/mL doses for both citrate and PVP coated AgNPs. Nanoparticle 
deposition was normalized to a calibration curve. Time effects showed PVP to be 
the more stable nanoparticle, with citrate settling out almost entirely after 24 
hours. This, in turn, means a larger portion of the administered citrate coated dose 
interacts with or is internalized by the adherent cells. Nanoparticles of vary size 
and surface chemistry behave differently and could induce different levels of 
toxicity and stress to cellular systems.    
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